drugset / Trial / NCT02034773

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773

Phase 1 Completed 64 enrolled Celgene Corporation
RandomizedSingle-groupDouble-blind

Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of CC-220 in healthy subjects and to evaluate the relative bioavailability of a formulated CC-220 capsule

Timeline

Start
2013-05
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Iberdomide Small molecule 0.3 mg Oral
Subject Iberdomide Small molecule 1 mg Oral

Indications

No indication recorded.